Anzeige
Mehr »
Login
Donnerstag, 09.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
NurExone Biologic: Erfahren Sie mehr über den Biotech-Gral!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
216 Leser
Artikel bewerten:
(0)

Educating, Informing, and Successfully Preparing the Marketplace for New Bio-Pharma Products

CHAPEL HILL, N.C., March 17, 2013 /PRNewswire/ --Given the rapid rate that the pharmaceutical marketplace is evolving at, it has become more critical than ever for companies with new product launches to effectively educate the marketplace upon market entry. While educating and shaping the market for new bio-pharma products has been critical to the development process for years, how companies are choosing to complete these tasks is quickly changing - resulting in new, strategic marketplace practices.

To analyze and understand these practices, research and consulting firm Best Practices, LLC developed a study that helps to pinpoint effective practices that will benefit thought leaders when preparing for a new product launch. The report, Educating KOLs, Physicians, Patients and Payers to Support Successful Product Launches, identifies and captures scores of market-education benchmarks, key practices, lessons learned, and operational pitfalls to avoid when informing and preparing the marketplace for new products.

The 139-page report contains almost 500 metrics to help inform launch leaders on the most effective type and timing of market education practices during the full development cycle. Executives and managers involved in market education efforts for new products can use this research to compare their market education tactics and strategies with those of leading organizations. Key study objectives included:

  • Identification of Key Education Tactics for Thought Leaders, Physicians, Patients, and Payers
  • Identification of Key Timing for Educational Activities for KOLs, Physicians, Patients and Payers
  • Assessment of Key Market Education Practices, including Thought Leader Activities, CME, Scientific Publication Strategy and Tactics, Patients and Patient Advocacy Education, Clinical Trials & Payer Education
  • Description of Critical Market Education Pitfalls and Future Trends

The research project attracted 34 executives and managers from 26 leading pharmaceutical, biotech and medical device companies including 12 of the Top 20 pharma companies. Additionally, the research reflects on nine deep-dive interviews with selected participants.

Download a complimentary report summary, including sample best practices drawn from extensive primary research with executives at leading companies at: http://www3.best-in-class.com/rr1114.htm.

For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.

SOURCE Best Practices, LLC

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.